Using magnesium to treat bladder spasms after urologic procedures
Magnesium and Bladder Spasms Following Ambulatory Urologic Procedures
This study is testing if giving magnesium through an IV can help people feel better by reducing bladder spasms after certain urologic procedures.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 120 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Mayo Clinic Academic / other |
| Locations | 1 site (Rochester, Minnesota) |
| Trial ID | NCT05806996 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of intravenous magnesium in alleviating bladder spasms that may occur following ambulatory urologic procedures. Participants undergoing bladder invasive procedures at the Mayo Clinic will receive either magnesium or a placebo to assess the treatment's impact on post-operative bladder spasms. The study aims to determine if magnesium can provide relief and improve recovery outcomes for patients. It is a Phase 2 interventional trial focused on enhancing post-surgical care.
Who should consider this trial
Good fit: Ideal candidates are patients scheduled for bladder invasive procedures at the Mayo Clinic who can provide informed consent.
Not a fit: Patients with contraindications such as renal insufficiency, ongoing atrial fibrillation, or those who are pregnant may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly reduce bladder spasms and improve recovery for patients after urologic surgeries.
How similar studies have performed: While the use of magnesium for various medical conditions has been explored, this specific application for bladder spasms following urologic procedures is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: \- Be undergoing a bladder invasive procedure with or without planned urinary catheter on Mayo Clinic Gonda 7 Outpatient Procedure Center. Exclusion Criteria: * Are unable to grant informed consent or comply with study procedure. * Allergy or known sensitivity to magnesium or Renacidin. * Expected or high risk of bladder extravasation. * Ongoing atrial fibrillation prior to surgery. * Are undergoing emergency surgery. * Are pregnant. * Known hypermagnesemia. * Patients with neuromuscular weakness (e.g., Myasthenia gravis) due to magnesium's muscle weakening effect. * Patients with myocardial compromise or cardiac conduction defects because of magnesium's anti-inotropic effects. * Patients with renal insufficiency, glomerular filtration rate less than 30, since Magnesium is eliminated by the kidneys resulting in exaggerated rise in serum magnesium. * Patients with concomitant use of a calcium channel blocker since magnesium sulfate could act synergistically to suppress muscular contractility.
Where this trial is running
Rochester, Minnesota
- Mayo Clinic in Minnesota — Rochester, Minnesota, United States (Recruiting)
Study contacts
- Principal investigator: Gregory Nuttall, MD — Mayo Clinic
- Study coordinator: Tami Krpata
- Email: krpata.tami@mayo.edu
- Phone: 507-422-5768
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.